发明申请
- 专利标题: Combined pharmaceutical composition
- 专利标题(中): 组合药物组合物
-
申请号: US10588725申请日: 2005-02-08
-
公开(公告)号: US20070197602A1公开(公告)日: 2007-08-23
- 发明人: Hashime Kanazawa , Kouki Ishitani , Katsuichi Sudo , Naoto Tanimori
- 申请人: Hashime Kanazawa , Kouki Ishitani , Katsuichi Sudo , Naoto Tanimori
- 优先权: JP2004-032329 20040209
- 国际申请: PCT/JP05/01801 WO 20050208
- 主分类号: A61K31/44
- IPC分类号: A61K31/44 ; A61K31/19 ; A61K31/21 ; A61K31/35
摘要:
At least one hyperlipidemic agent selected from the group consisting of a fibrate compound (e.g., fenofibrate, bezafibrate, or a salt thereof) and an HMG-CoA reductase inhibitor (e.g., a statin compound, for example, pravastatin, atorvastatin, or salts thereof) is, as active ingredients, combined with an α-glucosidase inhibitor (e.g., voglibose, and acarbose) in the pharmaceutical composition of the present invention. The proportion of the α-glucosidase inhibitor may be about 0.001 to 50 parts by weight relative to 100 parts by weight of the hyperlipidemic agent. The present invention provides a pharmaceutical composition which is excellent in prophylactic and/or therapeutic effect on metabolic syndrome, hyperlipemia, diabetes, diabetes complications, etc, and has few side effects.